<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03668561</url>
  </required_header>
  <id_info>
    <org_study_id>2017_01</org_study_id>
    <secondary_id>2017-A02098-45</secondary_id>
    <nct_id>NCT03668561</nct_id>
  </id_info>
  <brief_title>the Effect of the CALIGALOC Orthosis on Standing and Walking of Hemiparetic Patients With Ankle Varus</brief_title>
  <acronym>CALIGALOC</acronym>
  <official_title>Evaluation of the Effect of the CALIGALOC Orthosis on Standing and Walking of Hemiparetic Patients With Ankle Varus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the benefit of an anti-varus ankle foot orthosis (CALIGALOC, Bauerfeind) on gait
      and balance parameters in hemiparetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>10-meter walk test (in seconds)</measure>
    <time_frame>comparison between baseline and 15 days</time_frame>
    <description>Maximum gait velocity, from a standing start</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of gait temporospatial parameters by GaitRite®</measure>
    <time_frame>comparison between baseline and 15 days</time_frame>
    <description>Specific temporal and spatial parameters of gait will be measured with the GaitRite gait evaluation system: gait cadence, hemiparetic step length, spatial asymmetry, swing and stance times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Posturographic analysis during static upright stance (center of pressure surface)</measure>
    <time_frame>comparison between baseline and 15 days</time_frame>
    <description>Assessment of displacements of the center of pressure during quiet upright standing for 30s, using a Zebris platform</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baropodometric analysis during gait</measure>
    <time_frame>comparison between baseline and 15 days</time_frame>
    <description>Assessment of the paretic footprint during gait, using the Zebris platform</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait endurance (2-minute walk test)</measure>
    <time_frame>comparison between baseline and 15 days</time_frame>
    <description>Assessment of maximum gait perimeter during a 2mwt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of walking function</measure>
    <time_frame>comparison between baseline and 15 days</time_frame>
    <description>Lower Limb Function assessment scale (LL-FAS, Allart et al. 2015) functional subscores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of the wearing of the Caligaloc orthosis assessed by visual analog scale</measure>
    <time_frame>at 15 days</time_frame>
    <description>visual analog scale (0=major discomfort - 10=excellent comfort)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hemiparesis</condition>
  <condition>Varus Deformity of Equine Carpus</condition>
  <arm_group>
    <arm_group_label>Treatment (CALIGALOC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wearing of the Caligaloc orthosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Caligaloc</intervention_name>
    <description>15 days of wearing of the Caligaloc orthosis</description>
    <arm_group_label>Treatment (CALIGALOC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemiparesis at &gt; 3 months (whatever the etiology)

          -  varus or equinovarus foot disturbing the stance phase of gait

          -  Able to walk at least 10m, with or without assistive device

        Exclusion Criteria:

          -  unable to walk 10m

          -  Botulinum toxin injection less than 3 months before inclusion

          -  history of neurological or locomotor pathology in addition to the etiology of
             hemiparesis

          -  Severe comprehension troubles

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne Allart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Etienne Allart, MD</last_name>
    <phone>3 20 44 48 71</phone>
    <phone_ext>+33</phone_ext>
    <email>etienne.allart@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Swynghedau, CHI</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Etienne Allart, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>hemiplegia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

